My experience with options has been I'm better off using them as a long term leveraged position like LEAPS, instead of short term dice rolls. They are so dangerous and can murder your account in a hurry, especially if you have early success and think you're super smart lol. As CH said, they are also can provide short term insurance through puts for your long term holdings if the stock market tanks.I still have my ETH that I bought a while ago. Not sure whether it's worth it to cash out now and enjoy the gains, or keep holding and use it as a fun little extra to watch and pay attention to.
Options, though, confuse the heck out of me. Part of me says that I should be able to learn and maybe use them, but there's another part of me that doesn't want to learn lest I enjoy them too much, and just stick with basic buying and selling.
Bojo sees 2021 revenue at $1.2-1.3b. Around double what they achieved in 2020. With NY and NJ on the horizon I suspect there could be another doubling when they're both online.![]()
Curaleaf Reports Record Second Quarter 2021 Results
- Second quarter 2021 Revenue(1) of $312 million, up 20% sequentially and 166% YoY - Second quarter 2021 Adjusted EBITDA margin of 28% on core U.S. operations, up 400 bps QoQ - Second quarter 2021...ir.curaleaf.com
Hey look weed companies still make money. 1.25b annual run rate. Profitability metrics obviously not in line with peers but overall these are big boy numbers. Big growth and a nice beat. They usually provide next quarter guidance on their call so I'll be back to report that!
Verano tomorrow morning, clashing with an enormous share unlock that the shorts have been running with for weeks. Curious to see how that plays out. ~$200m in revenues (50% qoq growth) is likely there.
The tesla of biotech. Fundamentally overvalued by just about every metric. Heavily shorted, angry angry shorts all over the twitters, etc. A fun story.other vaccine names have also gone apeshit
sadly, I did not hold a runner in MRNA
![]()
Did 199m which is well above analyst estimates (but in line with mine). Profitability tanked on first glance but due to several IFRS accounting impacts from their m&a action, they had a bunch of 1 time adjustments on the record that made things look a touch worse than they were. These issues will be long gone by the end of the year. They also mentioned that they will not raise cash by diluting the stock; they will find non-dilutive ways to do this if required. That's a big boy move. Less of a need to raise cash anyway when your Cap Ex is self funded by cash from operations.Verano tomorrow morning, clashing with an enormous share unlock that the shorts have been running with for weeks. Curious to see how that plays out. ~$200m in revenues (50% qoq growth) is likely there.